Status:
UNKNOWN
Benefits of Amantadine in Patients With Coma State
Lead Sponsor:
Dokuz Eylul University
Conditions:
Coma; Prolonged
Amantadine
Eligibility:
All Genders
18-65 years
Brief Summary
The study was a single center observational-prospective study and approved by local ethics committee. Patients in coma state due to traumatic brain injury, cardiac arrest or ischemic stroke who are ol...
Eligibility Criteria
Inclusion
- ≥18 years, ≤ 65 years
- GCS score ≤ 8
- Coma state due to ischemic stroke, brain hemorhage, anoxic brain damage
Exclusion
- \<18 years, \> 65 years
- Patients admitted to the critical care without diagnosis of coma state
- Patients admitted to critical care with coma state that are not duo to ischemic stroke, brain hemorhage, anoxic brain damage
- Metastatic malignant neoplazm
- Congenital or acquired brain function problem (cerebral palsy, autism etc)
- Patients with amantadine allergy
- Progressive degenerative diseases (Alzheimer, Parkinson diseases etc)
Key Trial Info
Start Date :
March 1 2016
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 1 2019
Estimated Enrollment :
56 Patients enrolled
Trial Details
Trial ID
NCT03443037
Start Date
March 1 2016
End Date
July 1 2019
Last Update
September 6 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dokuz Eylul University
Izmir, Turkey (Türkiye)